Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/943
Title: The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease.
Authors: Kikuchi, Kiyoshi
Salunya Tancharoen
ศรัณยา ตันเจริญ
Takeshige, Nobuyuki
Yoshitomi, Munetake
Morioka, Motohiro
Murai, Yoshinaka
Tanaka, Eiichiro
Mahidol University. Faculty of Dentistry. Department of Pharmacology
Keywords: Cardiovascular disease;Edaravone;Free radical scavenger;Open Access article
Issue Date: Jul-2013
Citation: Kikuchi K, Tancharoen S, Takeshige N, Yoshitomi M, Morioka M, Murai Y, et al. The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 2013 Jul 4;14(7):13909-30.
Abstract: Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001. Free radicals play an important role in the pathogenesis of a variety of diseases, such as cardiovascular diseases and stroke. Therefore, free radicals may be targets for therapeutic intervention in these diseases. Edaravone shows protective effects on ischemic insults and inflammation in the heart, vessel, and brain in experimental studies. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic, and anti-cytokine effects in cardiovascular diseases and stroke. Edaravone has preventive effects on myocardial injury following ischemia and reperfusion in patients with acute myocardial infarction. Edaravone may represent a new therapeutic intervention for endothelial dysfunction in the setting of atherosclerosis, heart failure, diabetes, or hypertension, because these diseases result from oxidative stress and/or cytokine-induced apoptosis. This review evaluates the potential of edaravone for treatment of cardiovascular disease, and covers clinical and experimental studies conducted between 1984 and 2013. We propose that edaravone, which scavenges free radicals, may offer a novel option for treatment of cardiovascular diseases. However, additional clinical studies are necessary to verify the efficacy of edaravone.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/943
metadata.dc.identifier.url: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742225/pdf/ijms-14-13909.pdf
ISSN: 1422-0067 (electronic)
Appears in Collections:DT-Article

Files in This Item:
File Description SizeFormat 
dt-ar-salunya-2013-1.pdf261.03 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.